Altitude Sickness
13
0
0
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
46%
6 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (13)
The Psychophysiological Effect of Simulated and Terrestrial Altitude
The Effects of Artificial Air Negative Ions on High-Altitude Acclimatization, Serum HIF1, and PWC170 Index
Hypoxia Adaptation Promotes Cerebral Functional Connectivity With Neuromuscular Efficiency Decrement
HIGH Altitude CArdiovascular REsearch Latin America Population Study
Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD
Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude
Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)
Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
Inhaled Budesonide for Altitude Illness Prevention
Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness
AZ, MZ, and the Pulmonary System Response to Hypoxia
Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely
Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude